Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH‐Deficient Patients

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Arthritis care & research

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.23296PMID 28556555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2015cited by this paper
• Primaquine: the risks and the benefits

  2014influential reference
• Medications and Glucose-6-Phosphate Dehydrogenase Deficiency

  2010cited by this paper
• The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

  2009cited by this paper
• Glucose-6-phosphate dehydrogenase deficiency: a historical perspective.

  2008cited by this paper
• Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.

  2007cited by this paper
• Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.

  2006cited by this paper
• G6PD: population genetics and clinical manifestations.

  1996cited by this paper
• Enzymatic deficiency in primaquine-sensitive erythrocytes.

  1956cited by this paper

• KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.

  2024cites this paper
• Non‐biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases

  2024cites this paper
• KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis. Translated into Russian by E.V. Zakharova

  2024cites this paper
• Nicht‐Biologika‐Immunsuppressiva bei entzündlichen und autoimmunen Hautkrankheiten

  2024cites this paper
• Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review

  2023cites this paper
• G6PD deficiency—does it alter the course of COVID-19 infections?

  2023cites this paper
• G6PD Deficiency and COVID-19 in Burkina Faso: A Possible Link?

  2023cites this paper
• Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

  2022cites this paper
• [Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19

  2022cites this paper
• Occurrence of Methemoglobinemia due to COVID-19: A Case Report

  2022cites this paper
• In vitro assessment for cytotoxicity screening of new antimalarial candidates

  2022cites this paper
• COVID-19 in G6PD-deficient patients, oxidative stress, and neuropathology.

  2022cites this paper
• Hemolytic anemia in COVID-19

  2022cites this paper
• mTORC1 activation induced proximal tubular damage via the pentose phosphate pathway in lupus nephritis.

  2022cites this paper
• How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice

  2022cites this paper
• Hydroxychloroquine Therapy Led to the Diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in an Elderly Patient with COVID-19 Involvement: A Case Report and Review of the Literature

  2022cites this paper
• G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19)

  2021cites this paper
• Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents

  2021cites this paper
• Miejsce hydroksychlorochiny we współczesnej dermatologii

  2021cites this paper
• [Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19].

  2021cites this paper
• Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety Evidence

  2021cites this paper
• Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity

  2021cites this paper
• Pharmacogenetics Approach for the Improvement of COVID-19 Treatment

  2021cites this paper
• FOR EMERGENCY USE AUTHORIZATION On behalf of Dr ,

  2021cites this paper
• Safety of Long-Term Use of Four Common Conventional Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

  2021cites this paper
• Current status of therapeutic alternatives for COVID-19: A narrative review.

  2021cites this paper
• Value of antimalarial drugs in the treatment of lupus

  2021cites this paper
• WITHDRAWN: Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19

  2021cites this paper
• Knowledge on Hydroxychloroquine Prescription and Attitude toward its use in COVID-19 - A Survey-Based Study among Doctors

  2021cites this paper
• La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19

  2021cites this paper
• KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

  2021cites this paper
• Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose

  2020cites this paper
• Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase

  2020cites this paper
• Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a “humanized” G6PD A- mouse model

  2020cites this paper
• Lupus erythematosus tumidus in an adolescent with beta thalassemia minor successfully controlled with hydroxychloroquine

  2020cites this paper
• HEMOLYTIC ANEMIA AND METHEMOGLOBINEMIA DUE TO HYDROXYCHLOROQUINE USE FOR COVID-19 TREATMENT IN A GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT PATIENT

  2020cites this paper
• Considérations pour la prise en charge sécuritaire d’une infection au SRAS-CoV-2 au moyen de chloroquine, d’hydroxychloroquine et d’azithromycine

  2020cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report.

  2020cites this paper
• Adverse Drug Reactions During COVID-19 Treatment

  2020cites this paper
• Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead

  2020cites this paper
• Clinical, laboratory, and chest CT features of severe versus non-severe pediatric patients with COVID-19 infection among different age groups

  2020cites this paper
• I. Cloroquina / hidroxicloroquina y azitromicina. Revisión narrativa de seguridad

  2020cites this paper
• Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2

  2020cites this paper
• Review on Use of Hydroxychloroquine and Azithromycin in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

  2020cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• Castleman disease and SLE in a G6PD-deficient Marfan patient: a case report and literature review

  2020cites this paper
• PGPM_A_270069 463..484

  2020cites this paper
• Macrophage activation syndrome as an initial presentation of systemic lupus erythematosus with sensorineural hearing loss in a young male patient

  2020cites this paper
• Making decisions to mitigate COVID-19 with limited knowledge

  2020cites this paper
• Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

  2020cites this paper
• American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States

  2020cites this paper
• Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury

  2020cites this paper
• Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2

  2020cites this paper
• COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency

  2020cites this paper
• Hydroxychloroquine use in the COVID-19 patient.

  2020cites this paper
• Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID‐19 pandemic

  2020cites this paper
• Up to a Quarter of Children With Cancer Develop Breakthrough Clinical Varicella Despite Receiving Post-exposure Prophylaxis With Varicella Immunoglobulin: A Single Centre UK Experience Over 3 Years.

  2020cites this paper
• Hydroxychloroquine in Dermatology and Beyond: Recent Update

  2020cites this paper
• COVID-19 as an Acute Inflammatory Disease

  2020cites this paper
• Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.

  2020cites this paper
• Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach

  2020cites this paper
• Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?

  2020cites this paper
• A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine

  2020cites this paper
• Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase‐deficient patient with COVID‐19 infection

  2020cites this paper
• Facts, not Fear: Safety of Hydroxychloroquine.

  2020cites this paper
• From the trenches: inpatient management of coronavirus disease 2019 in pregnancy

  2020cites this paper
• Hydroxychloroquine use in COVID-19: what is the basis for baseline tests?

  2020cites this paper
• Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients

  2020cites this paper
• Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisal

  2020influential citation
• Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians

  2020cites this paper
• A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency

  2020cites this paper
• No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency☆

  2020cites this paper
• Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020

  2020cites this paper
• Pharmacogenomics of COVID-19 therapies

  2020cites this paper
• A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine

  2020cites this paper
• Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?

  2020cites this paper
• Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)

  2020cites this paper
• Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease

  2020cites this paper
• Systemic Drugs Used in Dermatology

  2019cites this paper
• Hydroxychloroquine in dermatology: New perspectives on an old drug

  2019cites this paper
• Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis

  2019cites this paper
• Rifampin-Induced Immune Hemolytic Anemia during Treatment of Pulmonary Tuberculosis in a Patient with Primary Sjogren's Syndrome

  2019cites this paper